Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on June 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Going-concern warning: recurring losses, net capital deficiency, and funding needs create substantial doubt within 12 months.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Going-concern warning: recurring losses, net capital deficiency, and funding needs create substantial doubt within 12 months
- 2025 product sales increased to $113.6M from $79.6M, but operating cash flow remained negative at $105.0M
- Cash and equivalents fell to $13.9M from $47.9M, while current debt reached $100.8M
- Net loss improved to $42.4M from $153.8M, aided by commercial and administrative expense reductions
- Severe concentration risk: a single customer represented over 97% of accounts receivable and AZSTARYS® drives product revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.